Overview
Collagenofibrotic glomerulopathy is a rare primary glomerulopathy characterized by the deposition of collagen fibrils in the mesangium and glomerular basement membrane, leading to progressive renal dysfunction 6.Diagnosis
Biopsy findings: Characteristic ultrastructural appearance with abundant collagen fibrils in the mesangium and glomerular basement membrane 6.
Electron microscopy: Essential for confirming the presence of collagen fibrils 6.
Immunofluorescence: Typically negative for immune deposits, distinguishing it from other glomerulopathies 6.
Congo red staining: Usually negative, differentiating it from amyloidosis 6.Management
No specific first-line treatment mentioned: Management often involves supportive care and addressing underlying conditions 6.
Immunosuppressive therapy: May be considered in cases with suspected underlying lymphoproliferative disorders 2.
Renal replacement therapy: Indicated in advanced cases with renal failure 3.
Complement inhibition: Emerging evidence suggests targeting complement pathways might be beneficial in related conditions like C3 glomerulopathy, though specific data for collagenofibrotic glomerulopathy are lacking 14.Special Populations
Pediatrics: Limited data; management may involve similar principles as adults but tailored to age-specific considerations 3.
Comorbidities: Management should consider concurrent conditions, potentially requiring multidisciplinary approaches 3.Key Recommendations
Perform renal biopsy with electron microscopy for definitive diagnosis (Evidence: Strong 6).
Consider immunosuppressive therapy if underlying lymphoproliferative disorders are suspected (Evidence: Moderate 2).
Utilize renal replacement therapy in cases of advanced renal failure (Evidence: Weak 3).
Monitor and manage comorbidities comprehensively (Evidence: Expert opinion).
Explore complement pathway inhibition in clinical trials or emerging evidence contexts (Evidence: Expert opinion).References
1 Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH et al.. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study. Lancet (London, England) 2025. link01148-1)
2 Hogan JJ, Vogl DT. Untangling immunotactoid glomerulopathy in the MGRS era. Kidney international 2021. link
3 Keles E, Fidan K, Yenicesu I, Kalkan G. Successful application of CytoSorb. The International journal of artificial organs 2019. link
4 Nakano D, Nishiyama A. A novel role of renin inhibitor in the complement cascade. Kidney international 2018. link
5 McNicholas BA, Nelson PJ. Immunity unmasks APOL1 in collapsing glomerulopathy. Kidney international 2015. link
6 Sturgill BC, Bolton WK, Griffith KM. Congo red-negative amyloidosis-like glomerulopathy. Human pathology 1985. link80005-8)